In what looks to be an unlikely headline, some experts may be ready to endorse finasteride treatment as a preferred choice in the prevention of prostate cancer. The drug, used to treat male pattern baldness and enlarged prostate, was black boxed by the FDA about ten years ago for use as a prostate cancer preventative, due to study results that showed a possible increase in more aggressive prostate tumors.
But, a new study indicates that among men aged 62, who received finasteride for a period of seven years, were 30% less likely to develop prostate cancer. And, the risk of less aggressive prostate tumors was reduced by more than 40%. Based on these results, it can be estimated that finasteride could prevent more than 70,000 cases of prostate cancer every year. While the study also showed a 3% increased likelihood of more aggressive tumors, it is thought that this could be the result of finasteride reducing the size of the prostate, and thereby making the tumors easier for physicians to find.
Are you or a loved one recovering from prostate cancer or radical prostatectomy? Read more about the UroStop device for preventing urine leakage during sex, or climacturia, after prostate surgery–developed by UroSciences.